Sensory gating in tobacco-naïve cannabis users is unaffected by acute nicotine administration.

What Was Tested

This randomized controlled trial looks at Therapeutic nicotine (patch, non-peptide).

The researchers aimed to determine if previously observed cannabis-associated deficits in sensory gating would be seen in cannabis users with no history of tobacco use, as evidenced by changes in the P50, N100, and P200 event-related potentials.

A secondary objective of this study was to examine the effects of acute nicotine administration on cannabis users with no tobacco use history.

Who Took Part

PubMed indexes the participants as teenagers, young adults and adults, men only.

Three components (P50, N100, P200) of the mid-latency auditory-evoked response (MLAER) were elicited by a paired-stimulus paradigm in 43 healthy, non-tobacco smoking male volunteers between the ages of 18-30.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

The participants were allocated by chance, so the Therapeutic nicotine (patch, non-peptide) group and the comparison group should start out alike.

Blinding on both sides kept the participants and researchers unaware of who received Therapeutic nicotine (patch, non-peptide).

Some participants received a placebo instead of Therapeutic nicotine (patch, non-peptide), giving a reference point.

Non-cannabis users (NU, n = 23) did not receive nicotine.

What Was Measured

Topics PubMed links to this paper include Acoustic Stimulation, Cannabinoid Receptor Agonists, Cannabis, Electroencephalography, Evoked Potentials, Auditory, Hallucinogens and Nicotine.

Author keywords: Event-related potential, MLAEP, Marijuana, Mid-latency auditory-evoked potential and P50.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Therapeutic nicotine (patch, non-peptide).

The abstract goes on to report its results in about 3 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2022 (Psychopharmacology), a journal based in Germany.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.